Analysts' Actions: C.R. Bard, Gap, GNC, Medtronic, Tyson Foods

NEW YORK (TheStreet) -- RATINGS CHANGES

Ambit Biosciences (AMBI) was initiated with a sell rating at TheStreet Ratings.

Gap (GPS) was upgraded at Canaccord Genuity to buy from hold. Twelve-month price target is $51. Company can continue to expand margins, Canaccord Genuity said.

C.R. Bard (BCR) was downgraded at Barclays to equal weight from overweight. Pressure on company due to its exposure to the peripheral vascular space, which is affected by Medtronic (MDT)/Covidien (COV) deal, Barclays said.

Franklin Resources (BEN) was upgraded at Goldman Sachs to buy from neutral. Better flow trends are being driven by emerging markets, and recent underperformance offers a cheap entry point, Goldman said.

GNC (GNC) was downgraded at J.P. Morgan to neutral. Company is seeing slower sales trends, and the CFO has left, J.P. Morgan said.

Gap (GPS) was upgraded at Canaccord Genuity to buy from hold. Twelve-month price target is $51. Company can continue to expand margins, Canaccord Genuity said.

Medtronic was upgraded at Barclays to overweight from equal weight. Driven by potential benefits from acquisition of Covidien, Barclays said. Twelve-month price target is $73.

North European Oil Royalty Trust (NRT) was downgraded to hold at TheStreet Ratings.

Sunpower (SPWR) was downgraded at J.P. Morgan to neutral. Valuation call, as the stock is up 35% year to date, J.P. Morgan said. Twelve-month price target is $40.

If you liked this article you might like

EY's Greene Sees More Med Tech, CRO Deals Ahead

Deals of the Week: Waiting for Clarity

Merger Buzz Drives Akorn to Top of Health Chart in April

Deals of the Week: Reason for Optimism

Good Medicine Makes for 3 Good Charts